Page 1342 - Williams Hematology ( PDFDrive )

1316 Part X: Malignant Myeloid Diseases Chapter 85: Essential Thrombocythemia 1317

70. Nieborowska-Skorska M, Kopinski PK, Ray R, et al: Rac2-MRC-cIII-generated ROS 83. Gisslinger H, Gotic M, Holowiecki J, et al: Anagrelide compared with hydroxyurea in
cause genomic instability in chronic myeloid leukemia stem cells and primitive progen- WHO-classified essential thrombocythemia: The ANAHYDRET Study, a randomized
itors. Blood 119:4253, 2012. controlled trial. Blood 121:1720, 2013.
71. Beer PA, Delhommeau F, Lecouedic JP, et al: Two routes to leukemic transformation 84. Garattini S, Bertele V: Non-inferiority trials are unethical because they disregard patients’
following a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115:2891, interests. Lancet 370:1875, 2007.
2010. 85. Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G: A systematic review of the
72. Abdel-Wahab O, Manshouri T, Patel J, et al: Genetic analysis of transforming events fetal safety of interferon alpha. Reprod Toxicol 33:265, 2012.
that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 70:447, 86. Kiladjian JJ, Chevret S, Dosquet C, et al: Treatment of polycythemia vera with
2010. hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980. J Clin
73. Jager R, Gisslinger H, Passamonti F, et al: Deletions of the transcription factor Ikaros in Oncol 29:3907, 2011.
myeloproliferative neoplasms. Leukemia 24:1290, 2010. 87. Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy of INCB018424, a JAK1
74. Milosevic JD, Puda A, Malcovati L, et al: Clinical significance of genetic aberrations in and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117, 2010.
secondary acute myeloid leukemia. Am J Hematol 87:1010, 2012. 88. Cervantes F, Vannucchi AM, Kiladjian JJ, et al: Three-year efficacy, safety, and survival
75. Landolfi R, Marchioli R, Kutti J, et al: Efficacy and safety of low-dose aspirin in poly- findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available
cythemia vera. N Engl J Med 350:114, 2004. therapy for myelofibrosis. Blood 122:4047, 2013.
76. Lanzkron S, Strouse JJ, Wilson R, et al: Systematic review: Hydroxyurea for the treat- 89. Harrison C: Pregnancy and its management in the Philadelphia negative myeloprolifer-
ment of adults with sickle cell disease. Ann Intern Med 148:939, 2008. ative diseases. Br J Haematol 129:293, 2005.
77. Sterkers Y, Preudhomme C, Lai JL, et al: Acute myeloid leukemia and myelodysplastic 90. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA: Antiplatelet agents for prevention
syndromes following essential thrombocythemia treated with hydroxyurea: High pro- of pre-eclampsia: A meta-analysis of individual patient data. Lancet 369:1791, 2007.
portion of cases with 17p deletion. Blood 91:616, 1998. 91. Liebelt EL, Balk SJ, Faber W, et al: NTP-CERHR expert panel report on the reproduc-
78. Weinfeld A, Swolin B, Westin J: Acute leukaemia after hydroxyurea therapy in polycy- tive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol
thaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity 80:259, 2007.
with therapeutic implications. Eur J Haematol 52:134, 1994. 92. Patel JP, Hunt BJ: Where do we go now with low molecular weight heparin use in
79. Bjorkholm M, Derolf AR, Hultcrantz M, et al: Treatment-related risk factors for trans- obstetric care? J Thromb Haemost 6:1461, 2008.
formation to acute myeloid leukemia and myelodysplastic syndromes in myeloprolifer- 93. Montanaro M, Latagliata R, Cedrone M, et al: Thrombosis and survival in essential
ative neoplasms. J Clin Oncol 29:2410, 2011. thrombocythemia: A regional study of 1,144 patients. Am J Hematol 89:542, 2014.
80. Tefferi A, Rumi E, Finazzi G, et al: Survival and prognosis among 1545 patients with 94. Hultcrantz M, Kristinsson SY, Andersson TM, et al: Patterns of survival among
contemporary polycythemia vera: An international study. Leukemia 27:1874, 2013. patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008:
81. Hanft VN, Fruchtman SR, Pickens CV, et al: Acquired DNA mutations associated with A population- based study. J Clin Oncol 30:2995, 2012.
in vivo hydroxyurea exposure. Blood 95:3589, 2000. 95. Price GL, Davis KL, Karve S, et al: Survival patterns in United States (US) medicare
82. Campbell PJ, Green AR: Management of polycythemia vera and essential thrombo- enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 9:e90299,
cythemia. Hematology 2005:201, 2005. 2014.

Kaushansky_chapter 85_p1307-1318.indd 1317 9/21/15 11:09 AM